Great Point Partners LLC Q3 2022 vs Q4 2022: A Detailed Comparison of Fund Holdings

The third quarter of 2022 was quite eventful in terms of changes in holdings of Great Point Partners LLC, a significant institutional investment manager providing services to high net worth individuals. This blog post will provide an in-depth analysis of the changes in holdings of the fund in Q3 2022 compared to Q4 2022. We will briefly discuss some of the top-performing stocks and the significant changes that took place in the holdings of the fund in the last quarter of 2022.

We noticed that Vaxcyte Inc (PCVX) witnessed an increase in the number of shares held by Great Point Partners LLC from 600,000 in Q3 2022 to 800,000 in Q4 2022 - a significant 166.4% increase. This change resulted in an increase in the value of the shares from $14,400 in Q2 2022 to $38360 in Q4 2022. Another notable stock that experienced similar changes was XENON PHARMACEUTICALS INC (XENE), where Great Point Partners LLC decided to maintain 850,000 shares in Q4 2022 just like it did in the previous quarter. There was a 9.2% increase in the market value of the shares between the third and fourth quarters of 2022th.

Some significant holdings that Great Point Partners LLC decided to sell entirely were TRICIDA INC (TCDA), REPLIMUNE GROUP INC (REPL), NGM BIOPHARMACEUTICALS INC (NGM), MAGENTA THERAPEUTICS INC (MGTA), and AEGLEA BIOTHERAPEUTICS INC (AGLE). The fund also wholly trimmed its holdings in several other companies such as MADRIGAL PHARMACEUTICALS INC (MDGL), MILESTONE PHARMACEUTICALS INC (MIST), and IMMUNOCORE HLDGS PLC (IMCR), just to mention a few.

In contrast, Great Point Partners LLC increased its holdings in several companies, some of which are ALPINE IMMUNE SCIENCES INC (ALPN), SEAGEN INC (SGEN), CYMABAY THERAPEUTICS INC (CBAY), and ACUMEN PHARMACEUTICALS INC (ABOS). The fund held 3,637,718 shares of ALPINE IMMUNE SCIENCES INC by the end of Q4 2022, which was a 7.7% increase from its 3,448,521 shares holdings in Q3 2022. SEAGEN INC (SGEN), a cancer therapy company, is another top holding of Great Point Partners LLC in Q4 2022. The fund increased its holdings in the company by 97.1%, bringing the number of shares held to 160,500. This move also resulted in an increase in the market value of the stock from $10,467 in Q3 2022 to $20,625 in Q4 2022.

Overall, Great Point Partners LLC showed a mixed investment strategy in Q4 2022 by selling some holdings while accumulating others. The fund's maneuvering does indicate an attempt to reinforce its focus on the most lucrative market sectors and high-performing stocks while abandoning those that have underperformed in its portfolio. It will be interesting to see how these holdings will work out in the coming quarters as they go through multiple pressures of changing market dynamics.

In conclusion, we hope this blog post provided some useful insights into the Great Point Partners LLC Q3 2022 vs Q4 2022 13F filings. The data indicates that the fund made some notable changes in its holdings, which may have resulted from market changes, company business models, and other factors that influence investment decisions. However, there may be alternative or additional factors that are not available in the 13F filings and behind their actions, so always take your investment decision wisely.